Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention

Rolf P. Kreutz; Glen Schmeisser; Benjamin Maatman; Andrea Schaffter; Anjan Sinha; Elisabeth von der Lohe; Jeffrey A. Breall

doi:10.1160/TH16-10-0496

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2017; 117(02): 426-428
DOI: 10.1160/TH16-10-0496

Letters to the Editor

Schattauer GmbH

Fibrin clot strength measured by thrombelastography and outcomes after percutaneous coronary intervention

Authors

Rolf P. Kreutz

¹Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
Glen Schmeisser

¹Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
Benjamin Maatman

¹Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
Andrea Schaffter

¹Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
Anjan Sinha

¹Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
Elisabeth von der Lohe

¹Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA
Jeffrey A. Breall

¹Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, Indiana, USA

Abstract

Supplementary Material to this article is available online at www.thrombosis-online.com.

Full Text

References

References
1 Gurbel PA, Bliden KP, Guyer K. et al. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46: 1820-1826.
2 Bitar A, Kreutz RP. Role of Thrombelastography (TEG) in Risk Assessment and Guidance of Antithrombotic Therapy in Patients with Coronary Artery Disease. Drug Dev Res 2013; 74: 533-540.
3 Kreutz RP, Owens J, Lu D. et al. Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel. Platelets 2015; 26: 358-363.
4 Kreutz RP, Bitar A, Owens J. et al. Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease. J Thromb Thrombolysis 2014; 38: 380-387.
5 Lu D, Owens J, Kreutz RP. Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes. Thromb Res 2013; 132: e94-98.
6 Kreutz RP, Owens J, Breall JA. et al. C-reactive protein and fibrin clot strength measured by thrombelastography after coronary stenting. Blood Coagul Fibrinolysis 2013; 24: 321-326.
7 Thygesen K, Alpert JS, Jaffe AS. et al. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020-2035.
8 Cutlip DE, Windecker S, Mehran R. et al. Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344-2351.
9 Mehran R, Rao SV, Bhatt DL. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123: 2736-2747.
10 Ang L, Thani KB, Ilapakurti M. et al. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention. J Am Coll Cardiol 2013; 61: 23-34.
11 Wiviott SD, Braunwald E, McCabe CH. et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
12 Wallentin L, Becker RC, Budaj A. et al. PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-1057.
13 Bonaca MP, Bhatt DL, Cohen M. et al. PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-1800.
14 Byrnes JR, Duval C, Wang Y. et al. Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin a-chain crosslinking. Blood 2015; 126: 1940-1948.
15 Schlimp CJ, Solomon C, Ranucci M. et al. The effectiveness of different functional fibrinogen polymerization assays in eliminating platelet contribution to clot strength in thromboelastometry. Anesth Analg 2014; 118: 269-276.